ASCO 2017: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

Chicago, IL ( Preclinical models show that c-Met promotes survival of renal cancer cells through the regulation of programmed death-ligand 1 (PD-L1). Due to the lack of data on the relationship between c-Met and PD-L1 in human clear cell renal cell carcinoma (ccRCC), the authors presented a study comparing c-Met expression between primary and metastatic sites in ccRCC tissues and evaluated the association with PD-L1 expression. 

Paired primary and metastatic samples from 45 ccRCC patients were included in this analysis. Only areas with predominant and highest Fuhrman nuclear grade (FNG) were selected. c-Met expression was evaluated by IHC using an anti-Met monoclonal antibody (MET4 Ab, VARI). PD-L1 expression was assessed by IHC. c-Met expression (average c-Met CS) between paired primary and metastatic samples were compared. Associations of c-Met expression with PD-L1 expression (+/-) and other clinical features were assessed as well. 

The final cohort included 45 primary ccRCCs and 54 corresponding metastases. c-Met expression was higher in metastatic sites compared to primary (c-Met CS: 55 vs. 28, p=0.0003) and was numerically-greater in PD-L1+ vs. PD-L1- tumors. Higher c-Met expression was associated with higher FNG and T-stage in both primary and metastatic sites, as shown in the table below. 

In summary, higher c-Met expression was demonstrated in metastases compared to paired primary tumors in our cohort of ccRCC. Although the observation that higher c-Met expression was shown in PD-L1+ tumors, it still requires further investigation.

Presented By: Aly-Khan A. Lalani, Dana-Farber Cancer Institute, Boston, MA

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
Twitter: @GoldbergHanan

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 - Chicago, Illinois, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.